Loading...
•
Sep 30, 2020
Evofem Biosciences Q3 2020 Earnings Report
Evofem Biosciences reported financial results for Q3 2020.
Key Takeaways
Evofem Biosciences reported its first quarter of product sales, with net product sales of $0.3 million following the U.S. commercial launch of Phexxi. The company also initiated its Phase 3 EVOGUARD trial and secured a $25 million strategic investment.
Launched Phexxi as the first and only hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.
Initiated EVOGUARD, the pivotal Phase 3 clinical trial to evaluate safety and efficacy of EVO100 for the prevention of chlamydia and gonorrhea in women.
Secured a $25 million strategic investment from Adjuvant Capital at a premium to market, with proceeds earmarked to fund EVOGUARD and expand global market access for Phexxi.
The Phase 3 AMPOWER study of Phexxi for prevention of pregnancy was published in the peer-reviewed journal Contraception.
Evofem Biosciences
Evofem Biosciences
Evofem Biosciences Revenue by Segment
Revenue by Segment
Net Product Sales Revenue
CapyFin.com Forward Guidance
Evofem Biosciences expects Phexxi to reach its full market potential based on key launch metrics, including the number of women who have taken advantage of the Phexxi Concierge Experience, Phexxi.com website visitors, and interest among healthcare providers. The company expects to file an NDA for EVO100 in 2022, assuming timely completion and positive study results.